Zenodo (CERN European Organization for Nuclear Research)
October 21, 2026
Shannon Green
preprint
Endogenous N,N-dimethyltryptamine (DMT) has been detected in mammals, but its physiological functions and the distribution of functionally relevant synthesis remain unresolved. This paper proposes prostatic tissue as a candidate peripheral site of synthesis. Oncology studies document indolethylamine N-methyltransferase (INMT) expression in human prostate samples, including adjacent...
TUScholarShare
October 19, 2026
Sara E Walton
Forensic toxicology relies heavily on foundational analytical chemistry techniques for the identification and characterization of drugs and toxins, and this work specifically focused on novel psychoactive substances (NPS). NPS are drugs that have newly emerged on the illicit or recreational drug market for use that circumvents legislation (i.e., “legal highs”) and cause significant risk to drug...
Frontiers in Psychiatry
October 14, 2026
Mathieu Seynaeve, Leonie Schneider, Ian Roullier et al.
BackgroundWhile psychedelic treatments for difficult-to-treat mental health conditions are advancing, participant perspectives remain under-explored. This study examined former participants’ experiences across recruitment, preparation, dosing, integration and study ending, and generated recommendations for future trials and treatment delivery.MethodsThis qualitative descriptive study, informed...
Molecular Neurobiology
October 12, 2026
Daiane Momo Daneluz, Alana Sueli Dos Santos, Silvana Regina De Melo et al.
Psychedelic drugs promote rapid neuroplasticity in brain regions affected by trauma exposure, such as the prelimbic (PL) cortex and the dorsal hippocampus (DH), being investigated as potential treatments for posttraumatic stress disorder. Ayahuasca (Aya) contains N,N-dimethyltryptamine, a classic psychedelic. Our previous work showed that Aya reduces fear expression by impairing fear memory...
Progress in neuro-psychopharmacology & biological psychiatry
October 6, 2026
Chad Collyer, Gia Han Le, Maryam Hassan et al.
Short-acting tryptamine psychedelics are emerging as candidate psychiatric therapeutics with pharmacological profiles that may offer practical advantages over longer-acting psychedelics. N,N-dimethyltryptamine (N,N-DMT) and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) differ in pharmacokinetic, receptor, and phenomenological properties, while zalsupindole is a putatively non-hallucinogenic...
Chemistry & Biodiversity
October 1, 2026
Renato Pinto De Sousa, William Cezar de Lima Silva, Caíque Lopes Duarte et al.
ABSTRACT: Malaria is a severe parasitic disease, with Plasmodium falciparum as one of the main etiological agents. The growing resistance to antimalarial drugs underscores the urgent need for the development of new therapeutic agents. This study describes the semisynthesis of eight new 1,4‐disubstituted 1,2,3‐triazole derivatives ( 3–10 ) from N , N ‐dimethyltryptamine ( 1 ), isolated from...
JAMA Network Open
September 29, 2026
Otto Simonsson, Melissa Bradley, Joshua Curtis Black et al.
This cross-sectional study describes health outcomes attributed to recent use of psilocybin, lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA), ibogaine, and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a nationally representative survey of US adults.
bioRxiv (Cold Spring Harbor Laboratory)
September 28, 2026
Gabriela Sawicka, Marian Martínez-Marín, Christopher Timmermann et al.
preprint
Psychedelic compounds such as N,N-dimethyltryptamine (DMT) induce rapid and profound changes in conscious experience, requiring neuroimaging measures that capture how brain dynamics evolve across space and time. Emerging evidence suggests that rotational (vortex-like) dynamics may contribute to the coordination of large-scale neural activity. Here, we introduce two vorticity-based metrics;...
Journal of Psychopharmacology
September 22, 2026
Maria Niedernhuber, Dila Suay, Bigna Lenggenhager et al.
BACKGROUND: Psychoactive serotonin 5-HT2A receptor agonists are potent modulators of awareness. Influential theories propose that psychedelics alter whole-brain dynamics by increasing neural signal diversity and dynamic flexibility. Beyond temporal variability, it is an open question whether psychedelics impact the characteristics of transient neural state sequences themselves. AIMS: Our goal...
Archives of Toxicology
September 21, 2026
Gloria Daziani, Lea Wagmann, Matthias D. Kroesen et al.
N,N-Dimethyltryptamine (DMT) is a naturally occurring substituted tryptamine used as a psychedelic drug for ritual purposes by various cultures. Derivatives were already found on the drug of abuse market, such as N1-tert-butoxycarbonyl-N,N-dimethyltryptamine (DMT-Boc). The aim of the current study was to investigate the toxicokinetics of DMT-Boc and three related DMT derivatives, by name...
Zenodo (CERN European Organization for Nuclear Research)
September 18, 2026
Kenjiro Shiraishi
preprint
Accepted manuscript of:Shiraishi K. Defining the Intervention Before Estimating Efficacy in DMT-Assisted Therapy. Journal of Psychopharmacology. 2026.DOI: 10.1177/02698811261488484 This Letter argues that DMT-assisted therapy for substance misuse should be evaluated as a complex intervention rather than as pharmacological exposure alone. It highlights the need to distinguish pharmacological...
The International Journal of Neuropsychopharmacology
September 9, 2026
B Richardson, S Socolow, Martha López-canul et al.
Abstract Background Recent clinical trials show that 5-MeO-DMT produces rapid antidepressant effects, yet the receptor mechanisms underlying these outcomes remain incompletely defined. Although 5-MeO-DMT is a high-affinity agonist at multiple serotonergic receptors, the relative contribution of 5-HT1A and 5-HT2A receptor signaling to its antidepressant-like actions has not been causally...
The International Journal of Neuropsychopharmacology
September 9, 2026
S Socolow, B Richardson, Sofia Nasini et al.
Abstract Background Major depression (MD) is a prevalent and debilitating disorder, characterized by anhedonia, persistent low mood, and learned helplessness, affecting up to 21% of adults over a lifetime. Chronic stress is a major environmental contributor to MD, and preclinical models of chronic mild stress (CMS) allow investigation of its behavioral and neurobiological consequences....
The International Journal of Neuropsychopharmacology
September 9, 2026
Romain Hacquet, P Pantiya, G Gotti et al.
Abstract Background Psychedelics such as psilocybin have demonstrated rapid and sustained antidepressant effects in humans, particularly when administered in carefully designed therapeutic environments (Borkel et al., 2024; Carhart-Harris et al., 2021). DMT and 5-MeO-DMT, distinguished by their brief duration of psychedelic effects, have also shown encouraging preliminary outcomes in depressive...
Brain Research
September 7, 2026
Eleni Kroupi, Helena Araujo, Cas Oosterveld et al.
N,N-Dimethyltryptamine (DMT), a potent serotonin-2A receptor agonist, elicits intense psychedelic experiences and has become a focus of interest in neuroscience and mental health research. While EEG studies of psychedelics typically report reduced alpha power, increased delta power, and enhanced signal complexity-primarily assessed using Lempel-Ziv complexity (LZc)-less is known about DMT's...
Journal of Psychoactive Drugs
September 7, 2026
Damian Swieczkowski, Aleksander Kwaśny, Wiesław Jerzy Cubała
This qualitative study examines self-reported experiences with 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) shared on Reddit to explore subjective reports, contextual influences, and perceived effects. A total of 120 posts from 24 discussion threads were purposively selected and thematically analyzed using an inductive, constructivist approach. The analysis resulted in 48 codes, which were...
Canadian Journal of Chemistry
September 4, 2026
Anton A. Homon, Pavithra Prasad, Jaxon Laramie et al.
The recent resurgence in psychedelic research has increased demand for these molecules for clinical studies. Due to the differences between national regulations and considering the dominance of the American market and its continued prohibition of many such molecules, the commercial availability of many of these compounds remains poor. This has also inhibited research into developing scalable...
Journal of Psychopharmacology
September 3, 2026
Katelijne V. van der Heijden, Gabriël E. Jacobs, Ellen James et al.
Serotonergic psychedelics, such as N,N-dimethyltryptamine (DMT), have shown therapeutic potential in various psychiatric disorders. However, DMT demonstrates pharmacokinetic (PK) variability and a short half-life. This exploratory study investigated the PK, pharmacodynamic (PD), and safety profile of CYB004, a deuterated DMT analogue, following intravenous administration in healthy volunteers....
Nutritional Psychiatry
September 1, 2026
Agnieszka Mechlińska, Aleksander Kwaśny, Michał Pastuszak et al.
ABSTRACT Psychedelic compounds exhibit diverse pharmacological and clinical effects, underscoring the need for further research and the development of clear guidelines to support their safe and effective clinical use. Growing interest in psychedelics has also increased attention toward the relationship between nutrition, dietary habits, and psychiatric disorders. This narrative review presents...
Journal of Psychopharmacology
August 31, 2026
Katelijne V. van der Heijden, Soma Makai‐bölöni, Amir Inamdar et al.
BACKGROUND: -dimethyltryptamine (DMT) might have therapeutic effects in various psychiatric disorders. AIMS: Prior to exploring this clinical potential, it is essential to determine an optimal administration regimen for DMT, explore the relationship between its pharmacokinetics (PK) and pharmacodynamics and identify potential sources of pharmacokinetic variability. METHODS: Therefore, DMT was...